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intraoperative revision for malplaced screws during the index procedure. Results 
of 10 case series and a European registry show rates of pedicle screw placement 
accuracy (0 mm to ≤ 2 mm) between 95% and 100% with 3D O-arm surgical imag-
ing with navigation compared to 84% - 95% reported for various current practice 
options from multiple meta-analyses. In addition, accuracy rates of between 72% 
and 92% have been reported for 2D C-arm without navigation. Economic studies 
demonstrated 3D O-arm surgical imaging with navigation has the potential to 
reduce the cost of fusion procedures in Europe and the USA by negating the need 
for pre-operative and post-operative imaging associated with current standard-
of-care, reducing the need for reoperations for screw revision, shortening length 
of procedures and OR time. It has been estimated that it could reduce the cost 
of hospitalization for spinal surgery by at least 3.8%. ConClusions: Current 
evidence shows 3D O-arm surgical imaging with navigation substantially reduces 
the human and financial burden of patients during spinal stabilization surgery 
compared with standard practice.
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objeCtives: To identify all relevant literature on clinical efficacy and safety evi-
dence for biosimilar infliximab (CT-P13) and comparator biological medications in 
rheumatoid arthritis and to conduct an up-to-date meta-analysis. Methods: The 
following comparators were considered for this analysis: abatacept, adalimumab, 
certolizumab, etanercept, golimumab, infliximab, rituximab and tocilizumab. A 
MEDLINE search was conducted until March 2013. The Cochrane Highly Sensitive 
Search Strategy was applied to identify randomized controlled publications and was 
combined with ‘arthritis, rheumatoid’ MeSH terms and drug names. Randomized, 
controlled, clinical trials with adults with moderate-to-severe RA and reporting end-
points for 6 months where the full paper can be obtained were included. Direct and 
indirect evidences were combined in a mixed treatment comparisons in a Bayesian 
framework. Efficacy measured by ACR50 endpoint and frequency of serious adverse 
events at 24-30 weeks were analysed. Results: Altogether 41 trials were included 
into current meta-analysis. The relative odds ratios (and 95% credible intervals) for 
ACR50 of biosimilar infliximab treatments compared to abatacept, adalimumab, cer-
tolizumab, etanercept, golimumab, rituximab, tocilizumab and infliximab were 1.0 
(0.3-3.8), 0.9 (0.2-3.4), 0.3 (0.1-1.4), 1.0 (0.2-4.2), 1.2 (0.3-5.1), 0.9 (0.2-3.6), 0.5 (0.1-2.2), 
1.0 (0.3-3.2), respectively. Similarly, relative odds ratios for serious adverse events 
were 1.9 (0.8-4.8), 2.0 (0.6-5.8), 0.7 (0.2-2.1), 2.0 (0.8-5.7), 1.5 (0.5-4.2), 1.1 (0.7-2.0), 1.3 
(0.8-2.2), 1.3 (0.8-2.1), respectively. ConClusions: The results showed that efficacy 
and safety of biosimilar infliximab is not significantly different from innovator 
infliximab and from other biologics.
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objeCtives: To compare the efficacy and safety of collagenase clostridium his-
tolyticum (CCH, Xiaflex®) injection with surgical fasciectomy for the treatment 
of Dupuytren’s contracture (DC). Methods: Systematic review and qualitative 
synthesis of comparative and non-comparative studies reporting efficacy (clini-
cal success, recurrence of contracture) and safety (complication) outcomes for 
patients undergoing fasciectomy for DC. Informal non-statistical comparison with 
outcomes from 3 pivotal placebo controlled trials and a long term follow-up study 
of DC patients treated with CCH. Results: Sixty-eight studies of fasciectomy were 
identified for inclusion in the review: 61 case series (52 retrospective; 9 prospec-
tive); 3 randomised controlled trials (RCTs), none of which permitted either a direct 
comparison with CCH or an indirect comparison via a common comparator; 1 RCT 
follow-up study; 2 prospective uncontrolled studies; 1 postal survey. Studies varied 
in terms of fasciectomy technique employed. Follow-up ranged from only immedi-
ately post-operatively up to 35 years post-operatively. Definitions of surgical success 
and recurrence varied, and were frequently ill-defined or less stringent than the 
robust definitions used in the CCH trials. In studies of fasciectomy where defini-
tions were judged as reasonably comparable to those used in the CCH trials (clinical 
success: 14 studies; recurrence: 40 studies), clinical success and recurrence rates for 
CCH and fasciectomy were comparable (clinical success: 63% vs 69% respectively, 
recurrence: 28% vs 21% at 4 years, respectively). Complication rates were greater 
for fasciectomy than for CCH. These included digital nerve or artery injury (3.3% vs 
0%), complex regional pain syndrome (3.6% vs 0.04%), joint stiffening (8.9% vs 0%), 
wound infection (6.2% vs 0%), and paraesthesia (4.3% vs 0%). Tendon ruptures were 
reported with CCH, but were infrequent (0.07%). ConClusions: CCH and surgical 
fasciectomy can be reasonably considered as comparable in terms of efficacy for 
the treatment of DC and superior in terms of safety.
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objeCtives: To examine the effectiveness of acupuncture net of sham effect and 
usual care, measured using EQ-5D, in the management of chronic, non-cancer pain 
in primary care. Systematic reviews of acupuncture for the conditions osteoarthritis 
PMS8
EQ-5d utility wEightS aSSociatEd with rESPonSE to trEatMEnt with 
Matrix aPPliEd autologouS culturEd chondrocytES (Maci) iMPlant 
and MicrofracturE for cartilagE dEfEctS of thE knEE
Saris D.1, Brittberg M.2, Mehin N.3, Dehle F.4, Dowton D.4, Kili S.5, Price A.6
1University Medical Center Utrecht, Utrecht, The Netherlands, 2Region Halland Orthopaedics, 
Kungsbacka, Sweden, 3Sanofi Biosurgery, Paris, France, 4OptumInsight, Sydney, Australia, 5Sanofi 
Biosurgery, Oxford, UK, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal 
Sciences (NDORMS), Oxford, UK
objeCtives: SUMMIT, a 2-year, multicenter, randomised trial, demonstrated signifi-
cant improvements in pain and function with matrix applied autologous cultured 
chondrocytes (MACI) implant versus microfracture in patients with symptomatic 
knee cartilage defects (NCT00719576). We present post-hoc results of the impact of 
treatment response on EQ-5D utility scores, and the overall incremental impact of 
treatment with MACI compared with microfracture over 2 years. Methods: Patients 
(aged 18-55) with Outerbridge Grade III/IV focal cartilage defect ≥ 3.0cm2were ran-
domised to receive MACI implant (n= 72) or microfracture (n= 72). Response to treat-
ment was defined as ≥ 10-point improvement from baseline in both the Knee Injury 
and Osteoarthritis Outcome (KOOS) pain and function scores at year 2. EQ-5D was 
evaluated at baseline, and years 1 and 2. Patients’ EQ-5D responses were scored using 
UK-tariffs. Utility values associated with responders and non-responders were esti-
mated based on results from both treatment arms combined. Incremental quality-
adjusted life year (QALY) gains were derived by multiplying the difference in response 
rates between the treatments with the difference in utility between responders and 
non-responders. Results: The mean utility score for all patients (n= 142) at base-
line was 0.481±0.296. Responders (n= 111) had an improvement in mean utility score 
from baseline of 0.352 (0.833-0.481) compared with 0.033 for non-responders (n= 29; 
0.514-0.481) at year 2. Significantly more patients treated with MACI responded to 
treatment than with microfracture (87.5% vs. 68.1%, respectively; p= 0.016), result-
ing in an incremental QALY gain of 0.11 for MACI compared with microfracture over 
2 years. ConClusions: At baseline, patients with chondral defects experienced a 
substantially reduced HRQoL. Significantly more patients responded to treatment 
with MACI versus microfracture, and this response was associated with substantial 
improvements in HRQoL. In this population, the higher response rate for MACI resulted 
in an incremental QALY gain of 0.11 compared with microfracture over 2 years.
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objeCtives: Treat-to-target strategies for the treatment of rheumatoid arthritis 
(RA), as recommended in current treatment guidelines, require the use of reliable 
early markers of treatment response in order to adapt therapy in a timely way in 
patients with insufficient response. The objective of this study was to evaluate 
and compare the performance of different clinical indicators in predicting clini-
cal response at one year. Methods: This was a post-hocanalysis of data from the 
RAPID1 randomised, placebo-controlled Phase III study. A total of 382 severe RA 
patients treated with certolizumab pegol 200mg and no prior TNF inhibitor were 
assessed by Week 12 (bW12) and at Week 52 (W52). “Insufficient response” was 
defined using the ACR response criteria, compared to baseline, DAS28 score (Δ < 1.2), 
HAQ score (Δ < 0.22) and CDAI (score< 22). The ability of insufficient response to 
these markers bW12 to predict failure to achieve ACR50 at W52, was compared in 
terms of positive predictive value (PPV), specificity and sensitivity. Results: At 
W52, 149 (38.1%) patients met the ACR50 response criterion. For all bW12 outcome 
indicators, the specificity and the PPV was > 80%. The higher PPVs were observed 
for bW12 ACR20 non response (1.00 [95%CI: 0.93-1.00]), bW12 reduction in DAS28 
(0.95 [95%CI: 0.82-0.99]) and bW12 CDAI score (0.93 [95%CI: 0.85-0.97]). For bW12 
ACR20 non response, bW12 reduction in DAS28 and bW12 CDAI score, specificities 
were respectively 1.00 (95%CI: 0.97-1.00), 0.99 (95%CI: 0.94-1.00) and 0.95 (95%CI: 
0.90-0.98). The highest sensitivity was observed for the bW12 ACR50 (0.70 [95%CI: 
0.63-0.76]). ConClusions: All these early response markers have high PPV and 
high specificity but low-to-moderate sensitivity: 80% to 100% of patients identified 
as “insufficient-responders” by W12 would fail to fulfil the ACR50 response at W52. 
Such predictability data for certolizumab pegol should help physicians to make early 
decisions about the potential discontinuation of the treatment.
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bACkgRound: Inaccurate pedicle screw placement and neurological or vascu-
lar injury during spinal instrumentation procedures is both costly and prevent-
able. objeCtives: To determine the comparative efficacy or effectiveness and 
value for money of the 3D O-arm Surgical Imaging System with Navigation during 
spinal stabilization surgery compared with standard practice. Methods: A search 
of Medical and Health Economic electronic databases (Embase, PubMed, HEED, 
NHS EED, Cochrane) and conference abstracts up to Nov. 2012 was conducted to 
identify studies evaluating the effectiveness, efficacy and economics of 3D surgical 
imaging with navigation. No time or language restrictions were applied. Results: 
Compared with current practice options, the 3D O-arm surgical imaging with navi-
gation was shown to significantly increase the accuracy of instrument placement, 
reduce surgeons’ and patients’ exposure to radiation, and offer the opportunity for 
